Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

TESLASCAN 37.9 MG — DIN 02241555

MANGAFODIPIR TRISODIUM : 37.9 MG · GE HEALTHCARE CANADA INC · SOLUTION · wholesale supply in Canada

Health Canada status: CANCELLED POST MARKET

What is TESLASCAN?

TESLASCAN 37.9 MG contains MANGAFODIPIR TRISODIUM : 37.9 MG. It is listed in the Health Canada Drug Product Database under DIN 02241555, held by GE HEALTHCARE CANADA INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 26-Jul-2010. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.

How is it supplied and stored?

Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.

Strength on the label37.9 MG
Dosage formSOLUTION
RouteINTRAVENOUS

Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.

Substance and classification

Active substanceMangafodipir
ATC codeV08CA05
AHFS class92:00.00
Biosimilar biologicNo

Health Canada record and identifiers

The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.

DIN (8-digit, as used in ordering)02241555
DIN (unpadded, as printed on some documents)2241555
Brand nameTESLASCAN
Generic / active ingredientMANGAFODIPIR TRISODIUM : 37.9 MG
Market authorization holderGE HEALTHCARE CANADA INC
Health Canada scheduleEthical
ATC codeV08CA05
ATC anatomical main groupV — Various
ATC therapeutic subgroupV08CA
Current statusCANCELLED POST MARKET
Status date26-Jul-2010
Original market date2000-09-15 00:00:00
Status sourceLive Health Canada DPD sync

Verify on the primary sources

Health Canada DPD record Approved product monograph (PDF)

What can be used instead?

Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.

2 · Same class — other molecules in ATC V08CA

MoleculeCanadian brandsDINsMarketedSourceable
GadobutrolGADOVIST 1.0 · PIXXOSCAN22Yes
Gadopentetic AcidGADOPENTETATE DIMEGLUMINE INJECTION · GADOPENTETATE DIMEGLUMINE INJECTION, USP · MAGNEVIST31Yes
GadodiamideOMNISCAN · OMNISCAN LIQ IV 287MG/ML21Yes
GadoteridolPROHANCE21Yes
Gadobenic AcidMULTIHANCE11Yes
Gadoteric AcidDOTAREM11Yes
Gadoxetic AcidPRIMOVIST11Yes
GadoversetamideOPTIMARK50Not in Canada
GadofosvesetABLAVAR · VASOVIST20Not in Canada
MangafodipirTESLASCAN10Not in Canada

A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.

Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.

Can this still be bought in Canada?

No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.

If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Why is there no price on this page?

Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Sources and disclaimer

Product data sourced from the Health Canada Drug Product Database and the approved product monograph (PDF). Health Canada status reconciled against the live DPD sync. Last reviewed 10 Sep 2026.

Nothing on this page is medical advice. Nexara Health is a licensed wholesale distributor and supplies licensed entities only; consumer orders are routed to a partner pharmacy. Alternatives tables describe supply, not clinical equivalence.

Health Canada Drug Product Database (DPD), DIN 02241555. Last reviewed 2026-09-10. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.